DRUG · Unmapped registry intervention
ALKS 3831
Find medicine records ·
Find other trials using this name
Clinical trial
A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
NCT02669758
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedA Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Schizophreniaverified · MONDO: schizophrenia
Interventions
ALKS 3831DRUG
Sponsors & collaborators
Alkermes, Inc.lead sponsor
Mapped research locations
ChicagoIllinois, United States1DallasTexas, United States1St LouisMissouri, United States1MiamiFlorida, United States1San DiegoCalifornia, United States1Las VegasNevada, United States1Little RockArkansas, United States1OrangeCalifornia, United States1SofiaBulgaria1DaytonOhio, United States1KharkivUkraine1BelgradeSerbia1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02669758 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.